Johnson & Johnson receives FDA approval for a subcutaneous injection therapy for lung cancer combination therapy.

Johnson & Johnson rose 0.4% in Friday's morning session after the company received approval from the US Food and Drug Administration: its RYBREVANT FASPRO can be used in combination with lazertinib for first-line treatment of EGFR mutant non-small cell lung cancer, allowing for subcutaneous injection in just 5 minutes.